Conditions: Homozygous Familial Hypercholesterolemia
Keywords: hypercholesterolemia familial hypercholesterolemia homozygous familial hypercholesterolemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 58
Healthy volunteers: no

Brief summary:
A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).

Detailed description:
Study Masking:

Part A: Open Label Part B: Double Blind

Arms:
arm 1: Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks. arm 2: Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks. arm 3: Participants received double-blind placebo subcutaneously once a month for 12 weeks.

Interventions: intervention 1: Evolocumab intervention 2: Placebo
Intervention descriptions: intervention 1: Administered by subcutaneous injection intervention 2: Administered by subcutaneous injection

Protocol document: